Autolus Therapeutics Stock Performance
| AUTL Stock | USD 3.32 0.05 1.53% |
The firm shows a Beta (market volatility) of 2.02, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Autolus Therapeutics will likely underperform. At this point, Autolus Therapeutics has a negative expected return of -0.12%. Please make sure to confirm Autolus Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Autolus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Autolus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 1.53 | Five Day Return 11.78 | Year To Date Return (51.46) | Ten Year Return (86.72) | All Time Return (86.72) |
1 | Autolus Therapeutics shareholder returns have been favorable, earning 76 percent in 1 year | 10/07/2024 |
2 | Autolus Therapeutics High-Growth UK Stock in Cancer Therapy | 10/17/2024 |
3 | Biotech Stocks Facing FDA Decision In November 2024 - Nasdaq | 10/30/2024 |
4 | Wellington Management Group LLPs Strategic Acquisition in Autolus Therapeutics PLC | 11/08/2024 |
5 | Autolus Therapeutics Reports Third Quarter 2024 Financial Resultsand Business Updates | 11/12/2024 |
6 | FMR LLCs Strategic Acquisition of Autolus Therapeutics PLC Shares | 11/13/2024 |
7 | Autolus stock upgraded as obe-cel approval drives optimism for commercial potential | 11/15/2024 |
8 | Great Point Partners LLC Has 10.21 Million Position in Autolus Therapeutics plc | 11/27/2024 |
| Begin Period Cash Flow | 382.8 M |
Autolus |
Autolus Therapeutics Relative Risk vs. Return Landscape
If you would invest 385.00 in Autolus Therapeutics on September 2, 2024 and sell it today you would lose (53.00) from holding Autolus Therapeutics or give up 13.77% of portfolio value over 90 days. Autolus Therapeutics is currently does not generate positive expected returns and assumes 4.7934% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Autolus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Autolus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Autolus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Autolus Therapeutics, and traders can use it to determine the average amount a Autolus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0243
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AUTL |
Estimated Market Risk
| 4.79 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Autolus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Autolus Therapeutics by adding Autolus Therapeutics to a well-diversified portfolio.
Autolus Therapeutics Fundamentals Growth
Autolus Stock prices reflect investors' perceptions of the future prospects and financial health of Autolus Therapeutics, and Autolus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Autolus Stock performance.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (21.14) % | ||||
| Current Valuation | 278.69 M | ||||
| Shares Outstanding | 266.12 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.85 X | ||||
| Price To Sales | 87.56 X | ||||
| Revenue | 1.7 M | ||||
| Gross Profit | (130.86 M) | ||||
| EBITDA | (156.77 M) | ||||
| Net Income | (208.38 M) | ||||
| Cash And Equivalents | 216.44 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 52.97 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.29 X | ||||
| Book Value Per Share | 1.79 X | ||||
| Cash Flow From Operations | (145.59 M) | ||||
| Earnings Per Share | (1.22) X | ||||
| Market Capitalization | 883.52 M | ||||
| Total Asset | 375.38 M | ||||
| Retained Earnings | (878.56 M) | ||||
| Working Capital | 230.56 M | ||||
| Current Asset | 102.22 M | ||||
| Current Liabilities | 6.46 M | ||||
About Autolus Therapeutics Performance
By examining Autolus Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Autolus Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Autolus Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 43.30 | 41.14 | |
| Return On Tangible Assets | (0.56) | (0.58) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | (1.87) | (1.78) |
Things to note about Autolus Therapeutics performance evaluation
Checking the ongoing alerts about Autolus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Autolus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Autolus Therapeutics generated a negative expected return over the last 90 days | |
| Autolus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (130.86 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Great Point Partners LLC Has 10.21 Million Position in Autolus Therapeutics plc |
- Analyzing Autolus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Autolus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Autolus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Autolus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Autolus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Autolus Therapeutics' stock. These opinions can provide insight into Autolus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.